Progress towards with positive sign for long-awaited cancer vaccine
revolution is getting a little closer towards reality.New data from Moderna Inc. and Merck & Co. suggest that after decades of
failures, researchers are finally figuring out the right way to design a
vaccine that can teach immune cells how to recognize and combat tumors.
Earlier this month, the companies said that when used in concert with
Merck’s cancer immunotherapy Keytruda, Moderna’s mRNA cancer vaccine
reduced the risk of certain skin cancers from returning or patient deaths
by 44% compared with Keytruda alone.It’s the first time an mRNA-based cancer vaccine has proven itself in a
randomized study, and with an unambiguously positive outcome. If that
result holds up in larger trials, it would be a huge advance both for the
mRNA technology behind Covid vaccines and for the field of cancer vaccines
in general.But speedy steps needed to reach melanoma patients and developing a wi
revolution is getting a little closer towards reality.New data from Moderna Inc. and Merck & Co. suggest that after decades of
failures, researchers are finally figuring out the right way to design a
vaccine that can teach immune cells how to recognize and combat tumors.
Earlier this month, the companies said that when used in concert with
Merck’s cancer immunotherapy Keytruda, Moderna’s mRNA cancer vaccine
reduced the risk of certain skin cancers from returning or patient deaths
by 44% compared with Keytruda alone.It’s the first time an mRNA-based cancer vaccine has proven itself in a
randomized study, and with an unambiguously positive outcome. If that
result holds up in larger trials, it would be a huge advance both for the
mRNA technology behind Covid vaccines and for the field of cancer vaccines
in general.But speedy steps needed to reach melanoma patients and developing a wi
